EGD Surveillance in Cirrhosis
All patients with cirrhosis should undergo screening EGD at the time of diagnosis, with subsequent surveillance intervals determined by initial findings and degree of hepatic compensation 1.
Initial Screening
Perform EGD once cirrhosis is established to identify and grade varices 1. This screening is critical because the point prevalence of medium/large varices requiring prophylaxis is only 15-25%, meaning most patients either have no varices or small varices not yet requiring treatment 1.
Variceal Grading
- Small varices: ≤5 mm or minimally elevated veins
- Large varices: >5 mm or occupying >1/3 of esophageal lumen
- Document presence of red wale marks or red spots (high-risk features) 1
Surveillance Intervals Based on Initial Findings
No Varices on Initial EGD
Compensated cirrhosis: Repeat EGD every 2-3 years 1
Decompensated cirrhosis: Repeat EGD annually 1
The rationale is that decompensated patients have more rapid variceal development and progression due to worsening portal hypertension.
Small Varices on Initial EGD
Repeat EGD every 1-2 years regardless of compensation status 1
Exception: If patient is started on nonselective beta-blockers for variceal prophylaxis, follow-up EGD is not necessary 1. However, beta-blockers are typically reserved for small varices with high-risk features (Child-Pugh B/C or red wale marks present) 1.
Medium/Large Varices
These patients require primary prophylaxis with nonselective beta-blockers or endoscopic variceal ligation (EVL), not just surveillance 1.
Post-Treatment Surveillance
After Variceal Obliteration with EVL
- Perform EVL every 1-2 weeks until obliteration is achieved
- First surveillance EGD: 1-3 months after obliteration
- Subsequent surveillance: Every 6-12 months to check for variceal recurrence 1
For secondary prophylaxis after variceal hemorrhage, the combination of nonselective beta-blockers plus EVL is recommended, with the same surveillance schedule 1.
When EGD Can Be Avoided
Patients already on nonselective beta-blockers (propranolol, nadolol, carvedilol) for other indications (e.g., hypertension) do not require screening EGD 1.
Important caveat: Patients on selective beta-blockers (metoprolol, atenolol) should be switched to nonselective agents rather than avoiding EGD 1.
Clinical Pitfalls
Non-invasive markers are insufficient: While platelet count, spleen size, liver stiffness, and other parameters have been studied, their predictive accuracy remains unsatisfactory for replacing endoscopic screening 1. Cost-effectiveness models suggesting empiric beta-blocker therapy without EGD do not account for recent evidence showing beta-blockers don't prevent variceal development and have significant side effects 1.
Capsule endoscopy: While pilot studies show promise for diagnosing varices, sensitivity remains unestablished and this modality is not yet ready for routine clinical use 1.
Decompensation triggers earlier surveillance: Any episode of hepatic decompensation (ascites, encephalopathy, jaundice) should prompt immediate EGD if not recently performed, followed by annual surveillance thereafter 1.
Risk Stratification Considerations
The 2022 ESGE guideline 2 emphasizes that patients with compensated advanced chronic liver disease and clinically significant portal hypertension (HVPG >10 mmHg or liver stiffness >25 kPa) should receive nonselective beta-blockers as primary prophylaxis even before varices develop, though this represents a more aggressive approach than traditional guidelines.
The surveillance intervals outlined above from the 2007 Hepatology guidelines 1 remain the standard of care and are consistently referenced across subsequent literature 3, 4. These intervals balance the natural history of variceal development against the cost, discomfort, and sedation risks of repeated endoscopy.